PapersFlow Research Brief
Cancer Diagnosis and Treatment
Research Guide
What is Cancer Diagnosis and Treatment?
Cancer Diagnosis and Treatment is the cluster of research addressing diagnosis, treatment, and molecular characterization of Cancer of Unknown Primary (CUP), focusing on metastatic patterns, molecular profiling to identify tissue of origin, immunohistochemical markers, diagnostic algorithms, and clinical management strategies.
This field encompasses 81,705 works on Cancer of Unknown Primary (CUP). Research covers metastasis, tissue of origin identification via molecular profiling, immunohistochemistry, and clinical management. Diagnostic algorithms and gene expression profiling support management of unknown primary tumours and soft tissue metastases.
Topic Hierarchy
Research Sub-Topics
Molecular Profiling for Tissue of Origin in CUP
This sub-topic covers gene expression arrays and next-generation sequencing to predict primary tumor sites in metastatic cancers. Researchers validate algorithms against histopathological standards.
Immunohistochemical Markers in CUP Diagnosis
Examines panels of antibodies like TTF-1, GATA3, and CK7/20 for distinguishing CUP subtypes. Studies assess sensitivity, specificity, and algorithmic integration for clinical decision-making.
Gene Expression Profiling in CUP Classification
Focuses on commercial assays like CancerTYPE ID and Pathwork for CUP subtyping. Research evaluates predictive accuracy across metastatic cohorts and concordance with clinical outcomes.
Diagnostic Algorithms for Cancer of Unknown Primary
Develops and validates stepwise protocols combining imaging, IHC, and genomics for CUP workup. Studies compare algorithm efficiency in reducing diagnostic delays and costs.
Clinical Management of CUP Metastatic Patterns
Analyzes prognostic implications of serosal, nodal, and soft tissue metastases in CUP. Researchers investigate empiric chemotherapy regimens and immunotherapy responses by pattern.
Why It Matters
Cancer Diagnosis and Treatment guides clinical management of patients with metastatic cancer lacking a known primary site, where molecular profiling and immunohistochemical markers identify tissue of origin to direct therapy. For example, in platinum-refractory recurrent squamous-cell carcinoma of the head and neck, nivolumab treatment resulted in longer overall survival than standard single-agent therapy, as shown in the CheckMate 141 trial (Ferris et al., 2016, "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck"). Staging systems like the "AJCC Cancer Staging Manual" (2016) and classifications such as "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" (Swerdlow, 2017) standardize diagnosis across oncology, enabling precise treatment in head and neck squamous cell carcinoma and soft tissue tumours.
Reading Guide
Where to Start
"AJCC Cancer Staging Manual" (2016) serves as the starting point because it provides foundational staging principles essential for understanding cancer diagnosis, including CUP cases, with 17,377 citations indicating its core reference status.
Key Papers Explained
"AJCC Cancer Staging Manual" (2016) establishes staging basics, which "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" (Swerdlow, 2017) builds upon for haematopoietic tumours and "The 2015 World Health Organization Classification of Lung Tumors" (Travis et al., 2015) extends to lung classifications. "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck" (Ferris et al., 2016) applies these to treatment outcomes in head and neck cancers, while "Head and neck squamous cell carcinoma" (Johnson et al., 2020) synthesizes epidemiology and management.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues on molecular profiling and gene expression for CUP tissue of origin, with classifications like "WHO classification of tumours of soft tissue and bone" (Fletcher, 2013) guiding soft tissue metastases. No recent preprints or news available, so frontiers remain in integrating immunohistochemistry with clinical algorithms from top-cited works.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | AJCC Cancer Staging Manual | 2016 | — | 17.4K | ✕ |
| 2 | WHO Classification of Tumours of Haematopoietic and Lymphoid T... | 2017 | Medical Entomology and... | 13.0K | ✓ |
| 3 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head an... | 2016 | New England Journal of... | 4.9K | ✓ |
| 4 | The 2015 World Health Organization Classification of Lung Tumors | 2015 | Journal of Thoracic On... | 4.4K | ✕ |
| 5 | Head and neck squamous cell carcinoma | 2020 | Nature Reviews Disease... | 3.7K | ✓ |
| 6 | Mesenchymal stem cells within tumour stroma promote breast can... | 2007 | Nature | 3.2K | ✕ |
| 7 | Pamidronate (Aredia) and zoledronate (Zometa) induced avascula... | 2003 | Journal of Oral and Ma... | 3.0K | ✓ |
| 8 | WHO classification of tumours of soft tissue and bone | 2013 | IARC Press eBooks | 2.9K | ✕ |
| 9 | American Association of Oral and Maxillofacial Surgeons Positi... | 2014 | Journal of Oral and Ma... | 2.8K | ✕ |
| 10 | A Human Cell Line From a Pleural Effusion Derived From a Breas... | 1973 | JNCI Journal of the Na... | 2.4K | ✕ |
Frequently Asked Questions
What is the role of nivolumab in head and neck cancer treatment?
Nivolumab treatment in patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck resulted in longer overall survival compared to standard single-agent therapy. This finding comes from the CheckMate 141 trial (Ferris et al., 2016, "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck"). The therapy targets advanced cases where prior treatments failed.
How does the AJCC Cancer Staging Manual support cancer diagnosis?
"AJCC Cancer Staging Manual" (2016) provides standardized staging for cancers, including those with unknown primary sites. It aids in classifying metastatic patterns and guiding treatment decisions. The manual has received 17,377 citations, reflecting its widespread use in oncology.
What defines head and neck squamous cell carcinoma?
Head and neck squamous cell carcinoma derives from mucosal epithelium in the oral cavity, pharynx, and larynx. Oral cavity and larynx cancers link to tobacco and alcohol use, while pharyngeal cases associate with human papillomavirus (Johnson et al., 2020, "Head and neck squamous cell carcinoma"). Diagnosis relies on classification systems like WHO guidelines.
What are key WHO classifications for cancer diagnosis?
"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" (Swerdlow, 2017) standardizes tumour classification in haematopoietic and lymphoid tissues. "The 2015 World Health Organization Classification of Lung Tumors" (Travis et al., 2015) updates lung tumour diagnostics. "WHO classification of tumours of soft tissue and bone" (Fletcher, 2013) covers soft tissue and bone tumours relevant to CUP metastases.
What complications arise from bisphosphonate treatments in cancer?
Pamidronate (Aredia) and zoledronate (Zometa) induce avascular necrosis of the jaws (Marx, 2003, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic"). The 2014 update by the American Association of Oral and Maxillofacial Surgeons addresses medication-related osteonecrosis of the jaw (Ruggiero et al., 2014, "American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update"). These guidelines inform risk management in cancer therapy.
Open Research Questions
- ? How can molecular profiling accuracy improve tissue of origin identification in CUP beyond current immunohistochemical markers?
- ? What metastatic patterns distinguish CUP from known primary cancers, and how do they influence diagnostic algorithms?
- ? Which gene expression profiles best predict treatment response in soft tissue metastases of unknown primary tumours?
- ? How do mesenchymal stem cells in tumour stroma specifically promote CUP metastasis mechanisms?
Recent Trends
The field maintains 81,705 works with no specified 5-year growth rate.
High citation persistence appears in classifications like "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues" (Swerdlow, 2017, 13,029 citations) and treatment trials such as "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck" (Ferris et al., 2016, 4,893 citations).
No recent preprints or news coverage available.
Research Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cancer Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers